Labcorp EVP Kyle exercises RSUs, holds 3,288 shares

Labcorp Holdings Inc. executive Kathryn W. Kyle, EVP and Chief Legal Officer, reported routine equity transactions involving restricted stock units (RSUs) and related common stock.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Labcorp Holdings Inc. executive Kathryn W. Kyle, EVP and Chief Legal Officer, reported routine equity transactions involving restricted stock units (RSUs) and related common stock. On February 6 and 7, 2026, RSUs covering 180 and 178 shares, respectively, were converted into Labcorp common stock at an exercise price of $0 per share.

To cover tax withholding obligations tied to these vestings, 61 shares were withheld at $277.20 per share on February 6 and another 61 shares at $274.01 per share on February 9, as indicated by transaction code F. After these transactions, Kyle directly owned 3,288.4574 shares of common stock and held 1,600 RSUs, which each represent the right to receive one share of Labcorp common stock.

Insider Trade Summary

358 shares exercised/converted

Exercise 6 txns

Insider Kyle Kathryn W

Role EVP, Chief Legal Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	61	$274.01	$17K
Exercise	Restricted Stock Unit	178	$0.00	$0.00
Exercise	Common Stock	178	$0.00	$0.00
Exercise	Restricted Stock Unit	180	$0.00	$0.00
Exercise	Common Stock	180	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	61	$277.20	$17K

Holdings After Transaction: Restricted Stock Unit — 1,600 contracts (Direct); Common Stock — 3,288.4574 shares (Direct)

Footnotes (5)

F1. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
F2. Stock withholding to satisfy tax withholding obligations.
F3. The Restricted Stock Units that have vested were part of a grant that vests in two equal annual installments beginning on February 6, 2026.
F4. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.
F5. The Restricted Stock Units vested on February 7, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Labcorp (LH) executive Kathryn W. Kyle report?

Kathryn W. Kyle reported RSU conversions and related tax share withholdings. RSUs for 180 and 178 shares converted to common stock at $0, while 61 shares were withheld at $277.20 and another 61 at $274.01 for tax obligations.

How many Labcorp (LH) common shares does Kathryn W. Kyle hold after these Form 4 transactions?

After the reported transactions, Kathryn W. Kyle directly holds 3,288.4574 Labcorp common shares. These reflect RSU conversions into stock and subsequent share withholdings for taxes, as disclosed in the Form 4’s non-derivative securities table.

What restricted stock unit (RSU) activity did Labcorp (LH) disclose for Kathryn W. Kyle?

The filing shows RSU conversions on February 6 and 7, 2026, covering 180 and 178 RSUs. Each RSU represents the contingent right to receive one Labcorp common share, and these vested as part of a grant vesting in two equal annual installments.

Why were Labcorp (LH) shares classified with transaction code F in Kathryn Kyle’s Form 4?

Transaction code F signals stock withholding to satisfy tax obligations. Labcorp withheld 61 shares at $277.20 and 61 shares at $274.01 from Kathryn W. Kyle’s vested stock to cover required tax withholding tied to her RSU vestings.

How many Labcorp (LH) restricted stock units does Kathryn W. Kyle hold after the transactions?

Following the RSU vestings and conversions, Kathryn W. Kyle holds 1,600 restricted stock units. The filing notes that this figure reflects the aggregate number of RSUs she owns, each representing the right to receive one Labcorp common share.

What is Kathryn W. Kyle’s role at Labcorp (LH) mentioned in the Form 4 filing?

The Form 4 identifies Kathryn W. Kyle as an officer of Labcorp, serving as Executive Vice President and Chief Legal Officer. She is not listed as a director or 10% owner, and the filing covers her personal equity compensation activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/10/2026 - 03:02 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kyle Kathryn W

(Last)

(First)

(Middle)

531 SOUTH SPRING STREET

(Street)

BURLINGTON

27215

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
LABCORP HOLDINGS INC. [ LH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/06/2026		M		180	A	⁽¹⁾	3,232.4574	D
Common Stock	02/06/2026		F⁽²⁾		61	D	$277.2	3,171.4574	D
Common Stock	02/07/2026		M		178	A	⁽¹⁾	3,349.4574	D
Common Stock	02/09/2026		F⁽²⁾		61	D	$274.01	3,288.4574	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	⁽¹⁾	02/06/2026		M			180	⁽³⁾	⁽³⁾	Common Stock	180	$0	1,778⁽⁴⁾	D
Restricted Stock Unit	⁽¹⁾	02/07/2026		M			178	⁽⁵⁾	⁽⁵⁾	Common Stock	178	$0	1,600⁽⁴⁾	D

Explanation of Responses:

1. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

2. Stock withholding to satisfy tax withholding obligations.

3. The Restricted Stock Units that have vested were part of a grant that vests in two equal annual installments beginning on February 6, 2026.

4. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

5. The Restricted Stock Units vested on February 7, 2026.

	/s/ Kathryn W. Kyle	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR